Date: 2011-02-01
Type of information: Private placement
Company: Mologen (Germany)
Investors:
Amount: €10 million
Funding type: private placement
Planned used: The proceeds will be used for the further development of the product pipeline. The blockbuster candidate, the colorectal cancer medication MGN1703, is supposed to be licensed this year.
Others: Mologen has successfully completed its capital increase. All of the 1,245,927 new shares were successfully placed. More than 40% of the subscription rights of existing shareholders were exercised. The shares offered in the context of the private placement were significantly oversubscribed already on the first day. On basis of the issue price of €8.00 per share, Mologen will receive approximately € 10 million.
Therapeutic area: Cancer - Oncology - Infectious diseases